NewsBenzingaLilly To Acquire Closely Held Neoplasm Therapy Developer Calytrix Bio For Up To $1.5B In Cash Lilly To Acquire Closely Held Neoplasm Therapy Developer Calytrix Bio For Up To $1.5B In Cash Benzinga 2026.11.16 12:23 (GMT+0) Open on Benzinga Other news Morgan Stanley Maintains Equal-Weight on W.W. Grainger, Raises Price Target to $1590 SpaceX's IPO Playbook Could Give Anthropic A $19B Buying Cushion—But There's A Catch What Is Going on With CoreWeave Stock on Monday? Morgan Stanley Maintains Underweight on Virgin Galactic Holdings, Lowers Price Target to $1.75 Occidental Petroleum Analyst Turns Bearish Due To Limited Volume Upside If You Invested $1000 In Monster Beverage Stock 5 Years Ago, You Would Have This Much Today